Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial

Morten Petersen; Jon T Andersen; Espen Jimenez-Solem; Kasper Broedbaek; Shoaib Afzal; Mette Nyegaard; Anders Børglum; Steen Stender; Christian Torp-Pedersen; Lars Køber; Henrik E Poulsen

doi:10.1097/fpc.0b013e3283540286

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial

Morten Petersen, Jon T Andersen, Espen Jimenez-Solem, Kasper Broedbaek, Shoaib Afzal, Mette Nyegaard, Anders Børglum, Steen Stender, Christian Torp-Pedersen, Lars Køber, Henrik E Poulsen

5 Citations (Scopus)

Abstract

OBJECTIVES: The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier). METHODS: Genotyping of 618 patients was carried out using the Sequenoms MassARRAY genotyping system. Outcome was all-cause mortality and statistics were calculated using a multivariable Cox proportional hazards model. Internal validation was performed using the bootstrap procedure. RESULTS: Eighty-seven of the 618 patients included in the study were treated with carvedilol. There was a significant interaction between the outcome of carvedilol treatment and the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous) and the gain-of-function AGT genotype (Thr174-homozygous) (Pinteraction=0.003; hazard ratio 2.19, 95% confidence interval 1.26-3.78, P=0.005). There was also a significant interaction when the downregulated ADRB2 genotype (Gln27-carrier) was added to the ADRB1/AGT combination (Pinteraction=0.0005; hazard ratio 2.67, 95% confidence interval 1.51-4.72, P=0.0007). Two hundred and four patients were treated with metoprolol. There was no interaction between metoprolol treatment and the specific genotype combinations as there was no difference in the overall survival. The validity of the results was supported by the bootstrap procedure. CONCLUSION: We found a doubling of the hazard of mortality in carvedilol-treated patients with the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous), the gain-of-function AGT genotype (Thr174-homozygous), and the downregulated ADRB2 genotype (Gln27-carrier). This might be valuable when stratifying chronic heart failure patients to the right β-blocker therapy.

Original language	English
Journal	Pharmacogenetics and Genomics
Volume	22
Issue number	10
Pages (from-to)	709-15
ISSN	1744-6872
DOIs	https://doi.org/10.1097/fpc.0b013e3283540286
Publication status	Published - Oct 2012

Access to Document

10.1097/fpc.0b013e3283540286

Cite this

Petersen, M., Andersen, J. T., Jimenez-Solem, E., Broedbaek, K., Afzal, S., Nyegaard, M., Børglum, A., Stender, S., Torp-Pedersen, C., Køber, L., & Poulsen, H. E. (2012). Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial. Pharmacogenetics and Genomics, 22(10), 709-15. https://doi.org/10.1097/fpc.0b013e3283540286

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial. / Petersen, Morten; Andersen, Jon T; Jimenez-Solem, Espen et al.
In: Pharmacogenetics and Genomics, Vol. 22, No. 10, 10.2012, p. 709-15.

Research output: Contribution to journal › Journal article › Research › peer-review

Petersen, M, Andersen, JT, Jimenez-Solem, E, Broedbaek, K, Afzal, S, Nyegaard, M, Børglum, A, Stender, S, Torp-Pedersen, C , Køber, L & Poulsen, HE 2012, 'Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial', Pharmacogenetics and Genomics, vol. 22, no. 10, pp. 709-15. https://doi.org/10.1097/fpc.0b013e3283540286

@article{8c6d31c08ac0479b95942efe7a240e16,

title = "Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial",

abstract = "OBJECTIVES: The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier). METHODS: Genotyping of 618 patients was carried out using the Sequenoms MassARRAY genotyping system. Outcome was all-cause mortality and statistics were calculated using a multivariable Cox proportional hazards model. Internal validation was performed using the bootstrap procedure. RESULTS: Eighty-seven of the 618 patients included in the study were treated with carvedilol. There was a significant interaction between the outcome of carvedilol treatment and the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous) and the gain-of-function AGT genotype (Thr174-homozygous) (Pinteraction=0.003; hazard ratio 2.19, 95% confidence interval 1.26-3.78, P=0.005). There was also a significant interaction when the downregulated ADRB2 genotype (Gln27-carrier) was added to the ADRB1/AGT combination (Pinteraction=0.0005; hazard ratio 2.67, 95% confidence interval 1.51-4.72, P=0.0007). Two hundred and four patients were treated with metoprolol. There was no interaction between metoprolol treatment and the specific genotype combinations as there was no difference in the overall survival. The validity of the results was supported by the bootstrap procedure. CONCLUSION: We found a doubling of the hazard of mortality in carvedilol-treated patients with the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous), the gain-of-function AGT genotype (Thr174-homozygous), and the downregulated ADRB2 genotype (Gln27-carrier). This might be valuable when stratifying chronic heart failure patients to the right β-blocker therapy.",

author = "Morten Petersen and Andersen, {Jon T} and Espen Jimenez-Solem and Kasper Broedbaek and Shoaib Afzal and Mette Nyegaard and Anders B{\o}rglum and Steen Stender and Christian Torp-Pedersen and Lars K{\o}ber and Poulsen, {Henrik E}",

year = "2012",

month = oct,

doi = "10.1097/fpc.0b013e3283540286",

language = "English",

volume = "22",

pages = "709--15",

journal = "Pharmacogenetics and Genomics",

issn = "1744-6872",

publisher = "Lippincott Williams & Wilkins",

number = "10",

}

TY - JOUR

T1 - Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure

T2 - a substudy of the ECHOS trial

AU - Petersen, Morten

AU - Andersen, Jon T

AU - Jimenez-Solem, Espen

AU - Broedbaek, Kasper

AU - Afzal, Shoaib

AU - Nyegaard, Mette

AU - Børglum, Anders

AU - Stender, Steen

AU - Torp-Pedersen, Christian

AU - Køber, Lars

AU - Poulsen, Henrik E

PY - 2012/10

Y1 - 2012/10

N2 - OBJECTIVES: The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier). METHODS: Genotyping of 618 patients was carried out using the Sequenoms MassARRAY genotyping system. Outcome was all-cause mortality and statistics were calculated using a multivariable Cox proportional hazards model. Internal validation was performed using the bootstrap procedure. RESULTS: Eighty-seven of the 618 patients included in the study were treated with carvedilol. There was a significant interaction between the outcome of carvedilol treatment and the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous) and the gain-of-function AGT genotype (Thr174-homozygous) (Pinteraction=0.003; hazard ratio 2.19, 95% confidence interval 1.26-3.78, P=0.005). There was also a significant interaction when the downregulated ADRB2 genotype (Gln27-carrier) was added to the ADRB1/AGT combination (Pinteraction=0.0005; hazard ratio 2.67, 95% confidence interval 1.51-4.72, P=0.0007). Two hundred and four patients were treated with metoprolol. There was no interaction between metoprolol treatment and the specific genotype combinations as there was no difference in the overall survival. The validity of the results was supported by the bootstrap procedure. CONCLUSION: We found a doubling of the hazard of mortality in carvedilol-treated patients with the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous), the gain-of-function AGT genotype (Thr174-homozygous), and the downregulated ADRB2 genotype (Gln27-carrier). This might be valuable when stratifying chronic heart failure patients to the right β-blocker therapy.

AB - OBJECTIVES: The aim of the present study was to determine whether carvedilol-treated chronic heart failure patients have a different prognosis when stratified for a specific combination of a gain-of-function genotype of the adrenergic β-1 receptor gene (ADRB1) (Arg389-homozygous), two gain-of-function genotypes of the angiotensinogen gene (AGT) (Thr174-homozygous and Thr235-homozygous), and a downregulated genotype of the adrenergic β-2 receptor gene (ADRB2) (Gln27-carrier). METHODS: Genotyping of 618 patients was carried out using the Sequenoms MassARRAY genotyping system. Outcome was all-cause mortality and statistics were calculated using a multivariable Cox proportional hazards model. Internal validation was performed using the bootstrap procedure. RESULTS: Eighty-seven of the 618 patients included in the study were treated with carvedilol. There was a significant interaction between the outcome of carvedilol treatment and the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous) and the gain-of-function AGT genotype (Thr174-homozygous) (Pinteraction=0.003; hazard ratio 2.19, 95% confidence interval 1.26-3.78, P=0.005). There was also a significant interaction when the downregulated ADRB2 genotype (Gln27-carrier) was added to the ADRB1/AGT combination (Pinteraction=0.0005; hazard ratio 2.67, 95% confidence interval 1.51-4.72, P=0.0007). Two hundred and four patients were treated with metoprolol. There was no interaction between metoprolol treatment and the specific genotype combinations as there was no difference in the overall survival. The validity of the results was supported by the bootstrap procedure. CONCLUSION: We found a doubling of the hazard of mortality in carvedilol-treated patients with the combination of the gain-of-function ADRB1 genotype (Arg389-homozygous), the gain-of-function AGT genotype (Thr174-homozygous), and the downregulated ADRB2 genotype (Gln27-carrier). This might be valuable when stratifying chronic heart failure patients to the right β-blocker therapy.

U2 - 10.1097/fpc.0b013e3283540286

DO - 10.1097/fpc.0b013e3283540286

M3 - Journal article

C2 - 22760495

SN - 1744-6872

VL - 22

SP - 709

EP - 715

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

IS - 10

ER -

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial

Abstract

Access to Document

Fingerprint

Cite this